Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 2/2010

01-04-2010 | Original Article

The risk of Parkinson’s disease in type 1 Gaucher disease

Authors: Gilberto Bultron, Katherine Kacena, Daniel Pearson, Michael Boxer, Ruhua Yang, Swati Sathe, Gregory Pastores, Pramod K. Mistry

Published in: Journal of Inherited Metabolic Disease | Issue 2/2010

Login to get access

Abstract

In Gaucher disease, defective lysosomal glucocerebrosidase due to mutations in the GBA1 gene results in lysosomal accumulation of glucocerebroside in mononuclear phagocytes and a multisystemic phenotype. Observations of occurrence of Parkinson’s disease in some patients with non-neuronopathic type 1 Gaucher disease (GD1) and their first degree relatives has led to the identification of GBA1 heterozygous mutations as a genetic risk factor for idiopathic Parkinson’s disease (PD). However, the magnitude of risk of PD in patients with known GD1 has not been determined, and it is not known whether GD1/PD represents a specific sub-phenotype of GD1 with distinctive genotype/phenotype characteristics. We estimated the risk of PD in a cohort of 444 consecutively evaluated patients with GD1 compared to that in the general population. Eleven patients developed parkinsonian syndrome during a 12-year follow-up period. The adjusted life-time risk ratio of PD in GD1 compared to that in the general population was 21.4 [95% confidence interval (95% CI) 10.7–38.3], with a higher risk in men compared to women. In our cohort, GD1/Parkinson’s disease phenotype (GD1/PD) was characterized by higher GD1 severity score, due to higher incidence of avascular osteonecrosis. The clinical spectrum of PD varied from mild to potentially life-threatening disease. All but one patient with GD1/PD phenotype had at least one N370S GBA1 allele. In conclusion, compared to the general population, patients with GD1 have an almost 20-fold increased life-time risk of developing PD.
Literature
go back to reference Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351:1972–1977CrossRefPubMed Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351:1972–1977CrossRefPubMed
go back to reference Bembi B, Zambito Marsala S, Sidransky E et al (2003) Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 61:99–101PubMed Bembi B, Zambito Marsala S, Sidransky E et al (2003) Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology 61:99–101PubMed
go back to reference Beutler E (2006) Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl 95:103–109CrossRefPubMed Beutler E (2006) Gaucher disease: multiple lessons from a single gene disorder. Acta Paediatr Suppl 95:103–109CrossRefPubMed
go back to reference Bras J, Paisan-Ruiz C, Guerreiro R et al (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 30:1515–1517CrossRefPubMed Bras J, Paisan-Ruiz C, Guerreiro R et al (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Portugal. Neurobiol Aging 30:1515–1517CrossRefPubMed
go back to reference Charrow J, Esplin JA, Gribble TJ et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158:1754–1760CrossRefPubMed Charrow J, Esplin JA, Gribble TJ et al (1998) Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158:1754–1760CrossRefPubMed
go back to reference Clark LN, Nicolai A, Afridi S et al (2005) Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord 20:100–103CrossRefPubMed Clark LN, Nicolai A, Afridi S et al (2005) Pilot association study of the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord 20:100–103CrossRefPubMed
go back to reference De Marco EV, Annesi G, Tarantino P et al (2008) Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy. Mov Disord 23:460–463CrossRefPubMed De Marco EV, Annesi G, Tarantino P et al (2008) Glucocerebrosidase gene mutations are associated with Parkinson’s disease in southern Italy. Mov Disord 23:460–463CrossRefPubMed
go back to reference Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet 351:1544–1546CrossRefPubMed Elstein D, Klutstein MW, Lahad A, Abrahamov A, Hadas-Halpern I, Zimran A (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher’s disease. Lancet 351:1544–1546CrossRefPubMed
go back to reference Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283CrossRefPubMed Gan-Or Z, Giladi N, Rozovski U et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70:2277–2283CrossRefPubMed
go back to reference Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353–1357CrossRefPubMed Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallett M, Sidransky E (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65:1353–1357CrossRefPubMed
go back to reference Grabowski GA (1997) Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1:5–12PubMed Grabowski GA (1997) Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1:5–12PubMed
go back to reference Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372:1263–1271CrossRefPubMed Grabowski GA (2008) Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet 372:1263–1271CrossRefPubMed
go back to reference Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2003) Burden of parkinsonism: a population-based study. Mov Disord 18:313–319CrossRefPubMed Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2003) Burden of parkinsonism: a population-based study. Mov Disord 18:313–319CrossRefPubMed
go back to reference Hermann G, Pastores GM, Abdelwahab IF, Lorberboym AM (1997) Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. Skeletal Radiol 26:687–696CrossRefPubMed Hermann G, Pastores GM, Abdelwahab IF, Lorberboym AM (1997) Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. Skeletal Radiol 26:687–696CrossRefPubMed
go back to reference Hruska KS, Goker-Alpan O, Sidransky E (2006) Gaucher disease and the synucleinopathies. J Biomed Biotechnol 2006:78549PubMed Hruska KS, Goker-Alpan O, Sidransky E (2006) Gaucher disease and the synucleinopathies. J Biomed Biotechnol 2006:78549PubMed
go back to reference Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 452:87–89CrossRefPubMed Kalinderi K, Bostantjopoulou S, Paisan-Ruiz C, Katsarou Z, Hardy J, Fidani L (2009) Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neurosci Lett 452:87–89CrossRefPubMed
go back to reference Lachmann RH, Wight DG, Lomas DJ et al (2000) Massive hepatic fibrosis in Gaucher’s disease: clinico-pathological and radiological features. QJM 93:237–244CrossRefPubMed Lachmann RH, Wight DG, Lomas DJ et al (2000) Massive hepatic fibrosis in Gaucher’s disease: clinico-pathological and radiological features. QJM 93:237–244CrossRefPubMed
go back to reference Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81:70–73CrossRefPubMed Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E (2004) Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81:70–73CrossRefPubMed
go back to reference Mayeux R, Denaro J, Hemenegildo N et al (1992) A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492–497PubMed Mayeux R, Denaro J, Hemenegildo N et al (1992) A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch Neurol 49:492–497PubMed
go back to reference Mistry PK, Sirrs S, Chan A et al (2002) Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77:91–98CrossRefPubMed Mistry PK, Sirrs S, Chan A et al (2002) Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77:91–98CrossRefPubMed
go back to reference Mitsui J, Mizuta I, Toyoda A et al (2009) Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66:571–576CrossRefPubMed Mitsui J, Mizuta I, Toyoda A et al (2009) Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol 66:571–576CrossRefPubMed
go back to reference Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89:691–694PubMed Neudorfer O, Giladi N, Elstein D et al (1996) Occurrence of Parkinson’s syndrome in type I Gaucher disease. QJM 89:691–694PubMed
go back to reference Neumann J, Bras J, Deas E et al (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132:1783–1794CrossRefPubMed Neumann J, Bras J, Deas E et al (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 132:1783–1794CrossRefPubMed
go back to reference Nichols WC, Pankratz N, Marek DK et al (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72:310–316CrossRefPubMed Nichols WC, Pankratz N, Marek DK et al (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72:310–316CrossRefPubMed
go back to reference Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105:4569–4572CrossRefPubMed Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105:4569–4572CrossRefPubMed
go back to reference Sato C, Morgan A, Lang AE et al (2005) Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord 20:367–370CrossRefPubMed Sato C, Morgan A, Lang AE et al (2005) Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord 20:367–370CrossRefPubMed
go back to reference Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ 321:21–22CrossRefPubMed Schrag A, Ben-Shlomo Y, Quinn NP (2000) Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ 321:21–22CrossRefPubMed
go back to reference Sidransky E (2006) Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 70:275–282CrossRefPubMed Sidransky E (2006) Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clin Genet 70:275–282CrossRefPubMed
go back to reference Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661CrossRefPubMed Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med 361:1651–1661CrossRefPubMed
go back to reference Socal MP, Bock H, Michelin-Tirelli K et al (2009) Parkinson’s disease and the heterozygous state for glucocerebrosidase mutations among Brazilians. Parkinsonism Relat Disord 15:76–78CrossRefPubMed Socal MP, Bock H, Michelin-Tirelli K et al (2009) Parkinson’s disease and the heterozygous state for glucocerebrosidase mutations among Brazilians. Parkinsonism Relat Disord 15:76–78CrossRefPubMed
go back to reference Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E (2008) Association between Parkinson’s disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 14:58–62CrossRefPubMed Spitz M, Rozenberg R, Pereira Lda V, Reis Barbosa E (2008) Association between Parkinson’s disease and glucocerebrosidase mutations in Brazil. Parkinsonism Relat Disord 14:58–62CrossRefPubMed
go back to reference Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214 Taddei TH, Kacena KA, Yang M, Yang R, Malhotra A, Boxer M, Aleck KA, Rennert G, Pastores GM, Mistry PK (2009) The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84:208–214
go back to reference Tan EK, Tong J, Fook-Chong S et al (2007) Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64:1056–1058CrossRefPubMed Tan EK, Tong J, Fook-Chong S et al (2007) Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. Arch Neurol 64:1056–1058CrossRefPubMed
go back to reference Tayebi N, Stern H, Dymarskaia I, Herman J, Sidransky E (1996) 55-Base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet 66:316–319CrossRefPubMed Tayebi N, Stern H, Dymarskaia I, Herman J, Sidransky E (1996) 55-Base pair deletion in certain patients with Gaucher disease complicates screening for common Gaucher alleles. Am J Med Genet 66:316–319CrossRefPubMed
go back to reference Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313–321CrossRefPubMed Tayebi N, Callahan M, Madike V et al (2001) Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73:313–321CrossRefPubMed
go back to reference Tayebi N, Walker J, Stubblefield B et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104–109CrossRefPubMed Tayebi N, Walker J, Stubblefield B et al (2003) Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab 79:104–109CrossRefPubMed
go back to reference Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ (2006) Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66:415–417CrossRefPubMed Toft M, Pielsticker L, Ross OA, Aasly JO, Farrer MJ (2006) Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. Neurology 66:415–417CrossRefPubMed
go back to reference Varkonyi J, Simon Z, Soos K, Poros A (2002) Gaucher disease type I complicated with Parkinson’s syndrome. Haematologia (Budap) 32:271–275CrossRef Varkonyi J, Simon Z, Soos K, Poros A (2002) Gaucher disease type I complicated with Parkinson’s syndrome. Haematologia (Budap) 32:271–275CrossRef
go back to reference Wu YR, Chen CM, Chao CY et al (2007) Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 78:977–979CrossRefPubMed Wu YR, Chen CM, Chao CY et al (2007) Glucocerebrosidase gene mutation is a risk factor for early onset of Parkinson disease among Taiwanese. J Neurol Neurosurg Psychiatry 78:977–979CrossRefPubMed
go back to reference Ziegler SG, Eblan MJ, Gutti U et al (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91:195–200CrossRefPubMed Ziegler SG, Eblan MJ, Gutti U et al (2007) Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Mol Genet Metab 91:195–200CrossRefPubMed
go back to reference Zimran A, Kay A, Gelbart T et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71:337–353CrossRef Zimran A, Kay A, Gelbart T et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71:337–353CrossRef
go back to reference Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200CrossRefPubMed Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200CrossRefPubMed
Metadata
Title
The risk of Parkinson’s disease in type 1 Gaucher disease
Authors
Gilberto Bultron
Katherine Kacena
Daniel Pearson
Michael Boxer
Ruhua Yang
Swati Sathe
Gregory Pastores
Pramod K. Mistry
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 2/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9055-0

Other articles of this Issue 2/2010

Journal of Inherited Metabolic Disease 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine